SOURCE: GeneThera, Inc.

April 10, 2007 09:00 ET

What Is Mad Cow Disease

WHEAT RIDGE, CO -- (MARKET WIRE) -- April 10, 2007 -- GeneThera, Inc. (OTCBB: GTHA).

Mad Cow disease is the common term for Bovine Spongiform Encephalopathy (BSE), a fatal disease that slowly destroys the nervous system in cattle. Since 1996, strong evidence has been collected for a causal relationship between ongoing outbreaks of Mad Cow disease in cattle and a disease in humans called variant Creutzfeldt-Jakob disease (vCJD). Both disorders, scientists believe, are caused by a protein called a prion.

From 1995 through August 2004, 147 human cases of vCJD were reported in the United Kingdom (UK), seven in France, and one each in Canada, Ireland, Italy, and the United States. Transmission of the Mad Cow agent to humans, leading to vCJD, is believed to occur via ingestion of cattle products contaminated with the BSE agent.

To the cattle industry, an outbreak of mad cow disease is an ever-looming nightmare. In the 1980s and '90s, Mad Cow infected 180,000 livestock in Europe and claimed dozens of human lives, devastating the British cattle industry. Britain, the United States and most other major cattle-producing nations have imposed stringent measures to control the disease, but another outbreak is a very real possibility and potentially devastating to the US Cattle Industry.

The Mad Cow disease in beef is nearly impossible to kill, even at very high temperatures. Public health control measures, such as surveillance, culling sick animals, or banning specified risk materials, have been instituted in many countries in order to prevent potentially Mad Cow infected tissues from entering the human food supply. The best Public Health control measure is testing of all cattle and culling the sick cattle from the healthy cattle.

SOURCE: CDC and Mayo Clinic


GeneThera, Inc. is a molecular biotechnology company located in Wheat Ridge, CO. The Company provides genetic diagnostic solutions for the veterinary and agricultural industries with future plans to include the health-care industry. The Company's proprietary diagnostic solution is based on a genetic expression assay, GEA™, a protocol designed to function on a highly automated Fluorogenic PCR platform. This platform enables GeneThera to offer tests that are presently not available from other technologies. The GEA is designed for a host of individual diseases, the current priority being Mad Cow Disease, Chronic Wasting Disease, a disease affecting elk and deer in North America; E.Coli 0157:H7 and Johnne's Disease, diseases affecting cattle worldwide.

"Safe Harbor" Statement: Certain statements in this release are "forward-looking" statements as defined in the Private Securities Litigation Reform Act of 1995. Such statements are subject to numerous risks and uncertainties. Actual results may vary significantly from the results expressed or implied in such statements. Factors that could cause actual results to materially differ from forward-looking statements include, but are not limited to, the Company's ability to meet the terms and conditions required to obtain its project financing, risks and delays associated with product development, risk of market acceptance of new products, risk of technology or product obsolescence, competitive risks, reliance on development partners and the need for additional capital.